Topics

PubMed Journals Articles About "UPLAT Placebo Thrombocytopenia" - Page: 2 RSS

08:02 EST 12th December 2019 | BioPortfolio

UPLAT Placebo Thrombocytopenia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest UPLAT Placebo Thrombocytopenia articles that have been published worldwide.

More Information about "UPLAT Placebo Thrombocytopenia" on BioPortfolio

We have published hundreds of UPLAT Placebo Thrombocytopenia news stories on BioPortfolio along with dozens of UPLAT Placebo Thrombocytopenia Clinical Trials and PubMed Articles about UPLAT Placebo Thrombocytopenia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of UPLAT Placebo Thrombocytopenia Companies in our database. You can also find out about relevant UPLAT Placebo Thrombocytopenia Drugs and Medications on this site too.

Showing "UPLAT Placebo Thrombocytopenia" PubMed Articles 26–50 of 1,000+

Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705).

Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2-29.1%). Unfortunately, there is no specific cure or vaccine for SFTS.


G-CSF administration results in thrombocytopenia by inhibiting differentiation of hematopoietic progenitors into megakaryocytes.

Hematopoietic stem cell transplantation (HSCT) plays an important role in the therapy of hematological malignancies and some nonmalignant diseases. Granulocyte colony-stimulating factor (G-CSF) is generally used to mobilize and collect hematopoietic stem cells from donors and accelerate neutrophil recovery in transplantation recipients. However, less attention has been paid to the fact that G-CSF administration might result in thrombocytopenia and enhance bleeding risk in HSCT. In this study, we investigate...

When therapeutic expectancies are violated: An fMRI study.

Positive and negative expectancies drive behavioral and neurobiological placebo and nocebo effects which in turn can have profound effects on patient improvement or worsening. However, expectations of events and outcomes are often not met in daily life and clinical practice. It is currently unknown how this affects placebo and nocebo effects. We have demonstrated that the violation of expectancies, such as when a discrepancy between what is expected and what is actually presented, reduces both placebo and n...


Timely diagnosis and treatment of neonatal alloimmune thrombocytopenia caused by anti HPA-3a antibody: A case report.

Neonatal alloimmune thrombocytopenia (NAIT) caused by anti HPA-3a antibody is rare, and the clinical features of the syndrome are not specific.

Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Thrombocytopenia is associated with life-threatening bleeding and is common in myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be developed to improve clinical decision making for patients with MDS with thrombocytopenia. Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) are promising immunogenic antigen candidates for immunotherapy, and their clinical effects on patients with MDS with thrombocytopenia are still not well understood. We performed a mu...

Meta-analysis of placebo group dropout in adult antidepressant trials.

Minimizing dropouts across antidepressant, placebo-controlled trials remains a major opportunity to improve the efficiency of trials. This meta-analysis investigated placebo dropout rate and its predictors in second generation antidepressant (SGA) for anxiety, depression and obsessive-compulsive disorder (OCD).

Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia.

Management of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therap...

Correlation of rotational thromboelastometry (ROTEM) parameters with platelet count and their ability to predict thrombocytopenia in dogs.

The study objectivs were to evaluate the correlation between platelet count (PLT) and rotational thromboelastometry (ROTEM) parameters and to determine ROTEM cut-off values for identification of thrombocytopenia in dogs. Medical records of 113 dogs with concurrent EXTEM (ROTEM activated by proprietary tissue factor), FIBTEM (EXTEM with added cytochalasin D) analysis and PLT were retrospectively reviewed. Signalment, treatment prior to analysis, hematocrit (HCT), EXTEM/FIBTEM maximum clot firmness (MCF, MCF)...

ECMO without anticoagulation in patients with disease-related severe thrombocytopenia: Feasible but futile?

Severe thrombocytopenia poses a high risk for bleeding thus representing a relative contraindication for anticoagulation and therefore ECMO. We herein report on a series of immunocompromised patients with severe thrombocytopenia undergoing long-term ECMO without systemic anticoagulation. We retrospectively identified 7 adult patients with anticoagulation withdrawal for ≥ 3 days (range 5-317) during venovenous ECMO therapy due to thrombocytopenia < 50 G / L treated in a university-affiliated hospital from ...

Intraoperative hypertension and thrombocytopenia associated with intracranial hemorrhage after liver transplantation.

Intracranial hemorrhage (ICH) is a devastating complication. Although hypertension and thrombocytopenia are well-known risk factors for ICH in the general population, their roles in ICH after liver transplantation (LT) have not been well established.

OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia.

Genetics studies on the placebo hypoalgesic effect highlight a promising link between single nucleotide polymorphisms (SNPs) in the dopamine, opioid, and endocannabinoid genes and placebo hypoalgesia. However, epistasis and replication studies are missing. In this study, we expanded on previous findings related to the 3 SNPs in the opioid receptor mu subunit (OPRM1 rs1799971), catechol-O-methyltransferase (COMT rs4680), and fatty acid amide hydrolase (FAAH rs324420) genes associated with placebo hypoalgesia...

Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus.

To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE).

Inadequate description of placebo and sham controls in a review of recent trials.

Poorly described placebo/sham controls inhibit appraisal of active intervention benefits and harms. The 12-item Template for Intervention Description and Replication (TIDieR) checklist was developed to improve the reporting of active intervention components. The extent to which TIDieR is used to guide description of placebo or sham control is not known.

Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma.

Genetic variation may differentially modify drug and placebo treatment effects in randomized trials (RCTs). In asthma, although lung function and asthma control improvements are commonplace with placebo, pharmacogenomics of placebo versus drug response remains unexamined. In a GWAS of subjective and objective outcomes with placebo treatment in Childhood Asthma Management Program (CAMP) of nedocromil/budesonide versus placebo (N=604), effect estimates for lead SNPs were compared across arms. The coughing/whe...

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.

Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment.

Comments on and assessments of "Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis".

Li et al recently published an article on the role of FCGR gene polymorphisms and immune thrombocytopenia (ITP). Their study is one of the first works to attempt a meta-analysis of FCGR polymorphisms in ITP. Their study clarifies some of the discrepancies in the literature.

Effects of oxytocin on placebo and nocebo effects in a pain conditioning paradigm: a randomized controlled trial.

Oxytocin has been shown to increase trust, decrease anxiety and affect learning as has been observed in conditioning paradigms. Trust, anxiety and learning are important factors that influence placebo effects. In this study we investigated whether oxytocin can increase placebo analgesia, decrease nocebo hyperalgesia, and influence extinction processes of both. Eighty male volunteers were assigned to a 40 IU of oxytocin nasal spray group, or to a placebo control group. Placebo analgesia and nocebo hyperalges...

Peri-procedural thrombocytopenia after aortic bioprosthesis implant: A systematic review and meta-analysis comparison among conventional, stentless, rapid-deployment, and transcatheter valves.

Thrombocytopenia has been shown to occur soon after surgical biological aortic valve replacement (AVR), and recently reported also after transcatheter valve implantation (TAVI). The mechanism underlying this phenomenon is still unknown, and its clinical impact on the peri-operative outcome has been poorly investigated.

Single-nucleotide polymorphisms (rs342275, rs342293, rs7694379, rs11789898, and rs17824620) showed significant association with lobaplatin-induced thrombocytopenia.

This study aimed to investigate single-nucleotide polymorphisms (SNPs) associated with lobaplatin-induced thrombocytopenia in patients with advanced lung cancer in China. Thirty-nine patients who received lobaplatin-based chemotherapy in the 307 Hospitals of Chinese People's Liberation Army from April 2017 to March 2018 were enrolled as study subjects. Peripheral blood DNA was extracted, and 79 candidate SNP positions were selected. A Sanger sequencing platform was employed to measure genotypes for locating...

The influence of personality traits on the placebo/nocebo response: A systematic review.

Some people might be more prone to placebo and nocebo responses than others depending on their personality traits. We aimed to provide a systematic review on the influence of personality traits on placebo and nocebo responses in controlled and uncontrolled studies.

Susceptibility of spotted doves (Streptopelia chinensis) to experimental infection with the severe fever with thrombocytopenia syndrome phlebovirus.

Severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging human pathogen naturally transmitted by ticks, has spread widely since it was first detected in 2010. Although SFTSV-specific antibodies have been detected in wild birds, these natural reservoir and amplifying hosts for the virus have not been well studied.

Effect of recombinant human thrombopoietin on endotoxin-induced thrombocytopenia in mice.

To investigate the effect of recombinant human thrombopoietin (rhTPO) on thrombocytopenia (TCP) induced by endotoxin lipopolysaccharide (LPS) in mice.

Aroma for Anxiety in Patients with Acute Coronary Syndrome: A Double-Blind Placebo-Controlled Trial.

This study evaluated the antianxiety effect of aroma (neroli oil) inhalation on patients with acute coronary syndrome (ACS). A double-blind, placebo-controlled randomized trial. This study was conducted in the Coronary Care Unit of Torfeh Hospital in Tehran, Iran, from September 2017 to February 2018. A total of 140 hospitalized ACS patients (mean age = 56.72 ± 11.38 years) Eligible patients were randomly assigned to citrus aroma and placebo groups to receive inhalation aromatherapy 2 days aft...

Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease.

Infection caused by the severe fever and thrombocytopenia syndrome virus (SFTSV) causes a hemorrhagic illness with a mortality between 20 to 40%. Initially recognized in 2009 in China, cases have additionally been documented in Japan and Korea although retrospective studies have documented seroprevalence since 1996. Although case rates have increased due to increased awareness and more widely available diagnostics, SFTSV infection remains rare with the highest rates documented in Korea for Jeju Province (3....

Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey.

Anti-heparin/platelet factor 4 antibody immune complexes resulting from heparin-induced thrombocytopenia (HIT) are removed by therapeutic plasma exchange (TPE). We sought to define TPE in HIT practice patterns using an international survey.


Quick Search